Indicative listing context
Neuralink Private-Market Access
Neuralink is a privately held company, so its shares are not available on any public stock exchange, and anyone searching how to invest in Neuralink before an IPO is looking at high-risk private-market exposure. Segmara is an independent research site where you can follow Neuralink's private-market activity with a dated indicative mark and a free email tracker. Segmara does not sell, broker, or arrange share purchases.
Get free Neuralink trackerIndicative private-market reference marks: not a quote and not an offer. Segmara does not sell, broker, or arrange share purchases.
Free research
Follow private companies by email.
The free tracker sends indicative marks by email. No card, no documents. Segmara does not sell, broker, or arrange share purchases.
Get the free trackerNeuralink round data and risk-adjusted context
Neuralink is a high-interest private company, but round analysis must account for clinical, regulatory, and long-duration development risk.
Official June 2025 raise
Reported pre-money valuation around the Series E
Neurotechnology timelines are not public-software timelines
| Stage | Date | Valuation / price signal | Why it matters |
|---|---|---|---|
| Seed / early | 2016-2021 | Formation and R&D phase | Early economics are not a reliable public retail dataset. |
| Series D | 2023 | Reported growth round | Useful mainly as a historical valuation reference. |
| Series E | June 2025 | $650M raise; reported ~$9B pre-money | The latest clear funding marker for private-share search intent. |
| IPO status | Current | No public Neuralink ticker | Buyers still need private-market access and a long risk horizon. |
Seed-to-IPO path
Illustrative completeness map. Longer bars mean stronger public data or more useful current pricing context, not lower risk.
AI-ready data summary
A structured extraction layer for this article: catalogue numbers, price context, chart values, and route-specific facts that search and AI systems can read directly from the page.
| Metric | Value | Context |
|---|---|---|
| Canonical route | /neuralink-private-market-access | Stable URL path for AI and search extraction. |
| Article title | Neuralink Private-Market Access | Main page topic. |
| Attached public sources | 4 | Number of citation links rendered at the bottom of the article. |
| Segmara listed companies | 51 | Live private-company listings in the public catalogue. |
| Priced listings | 37 | Catalogue listings with visible indicative or direct marks. |
| Listings without an indicative price | 14 | Catalogue listings where a public price is intentionally not invented. |
| Company | Neuralink | Named company covered by this page. |
| Symbol label | NEUR | Segmara display symbol; not a public stock ticker unless separately stated. |
| Sector | Biotechnology | Catalogue sector used for comparison and internal linking. |
| Listing structure | Indicative | How the listing is categorized on Segmara. |
| Segmara mark | $236.21/sh · as of August 14, 2026 | Visible listing mark, or no indicative price yet. |
| Sector peer count | 1 | Number of live Segmara listings in Biotechnology. |
| Structure peer count | 5 | Number of live Segmara listings categorized as Indicative. |
| Price rank | 10 of 37 | Ranked highest-to-lowest among Segmara listings with visible marks. |
| Price percentile | 76th | Percentile among visible Segmara catalogue marks. |
| Catalogue median mark | $92.58 | Median visible mark across priced Segmara listings. |
| Premium/discount to median | +155% | Difference between this listing mark and the catalogue median mark. |
Data fingerprint chart
| Stage | Timing | Price / valuation signal | Interpretation |
|---|---|---|---|
| Seed / early | 2016-2021 | Formation and R&D phase | Early economics are not a reliable public retail dataset. |
| Series D | 2023 | Reported growth round | Useful mainly as a historical valuation reference. |
| Series E | June 2025 | $650M raise; reported ~$9B pre-money | The latest clear funding marker for private-share search intent. |
| IPO status | Current | No public Neuralink ticker | Buyers still need private-market access and a long risk horizon. |
| Chart metric | Score | Interpretation |
|---|---|---|
| Listing price percentile | 76 / 100 | $236.21/sh · as of August 14, 2026 ranks 10 of 37 priced listings |
Analytical lens
Search intent
Searches like 'Neuralink Private-Market Access' are research questions: what a filing or a company statement confirms, what has only been reported, and what is still unknown.
What counts as a listing step
For an IPO, the primary record is a registration statement filed with the securities regulator of the listing market, such as an S-1 or F-1 on SEC EDGAR for a US listing. Funding rounds, valuations and secondary-market prices are context, not listing steps.
Segmara role
Segmara is an independent research site. It does not sell, broker, or arrange share purchases, and nothing on this page is investment advice.
How a company reaches a US listing
The SEC filing trail
DraftThe company can first submit a draft registration statement (DRS) for confidential SEC review.
S-1 or F-1The registration statement goes public on SEC EDGAR: Form S-1, or Form F-1 for many foreign companies. A company that used a draft must file publicly at least 15 days before its roadshow.
AmendmentsS-1/A or F-1/A amendments answer SEC comments, and one of them adds the expected price range.
PricingOnce the SEC declares the registration effective, the company sets the price with its underwriters and files the final prospectus, usually a 424B4.
First tradeThe shares start trading on the exchange named in the prospectus, such as Nasdaq or the NYSE.
Sources: SEC, March 3, 2025 · Investor.gov, October 14, 2022 · Regulation S-K Item 501 · SEC Form F-1.
Neuralink on SEC EDGAR
Segmara Pro checks SEC EDGAR for Neuralink filings every weekday and posts an alert in the members forum when one of these public filings appears. You can also check yourself with EDGAR full-text search.
Key takeaways
- Follow a company with the free tracker, email only.
- Consider time horizon, liquidity and the high risk of private-company exposure before any purchase.
- Any private-share route needs your own diligence on the seller and the terms.
Risk notes
- Neurotechnology exposure can involve long timelines and high uncertainty.
- Pre-IPO private shares or fund interests may be illiquid and hard to value.
- A research page does not create access, an advisory relationship, or a purchase path.
Public source links
Related reviews
Questions
Can I buy shares through Segmara?
No. Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases.
What can I do on Segmara?
Read the research pages, follow indicative marks with the free tracker (email only), check the free IPO calendar, or subscribe to Segmara Pro for a weekly IPO brief.
Is Segmara affiliated with the named company or platform?
No. Segmara is not affiliated with Neuralink or any named issuer, affiliate, investor, underwriter, or platform referenced on this page.
Can I buy Neuralink shares through Segmara?
No. Segmara is an independent research site. Segmara does not sell, broker, or arrange share purchases.
What does Segmara offer for Neuralink?
A dated indicative mark when one exists, source links and a free email tracker. Segmara Pro adds a weekly IPO brief.
How do I follow Neuralink?
Use the free Neuralink tracker (email only) and the free IPO calendar.
Next step
Track Neuralink free.
Get the indicative Neuralink price by email. Free, email only. No card, no documents, no brokerage account.
Get the free Neuralink tracker